ML-T7

ML-T7

• CAS Number: 459789-75-4
• UNSPSC Description: ML-T7 is a potent Tim-3 inhibitor. ML-T7 blocks Tim-3 interactions with PtdSer and CEACAM1. ML-T7 not only enhances the antitumor activity of adoptive transfer therapy with cytotoxic T lymphocytes (CTLs) and CAR T cells but also increases the effector function of T cell. ML-T7 promotes NK cells’ killing activity against tumor cells and DC antigen-presenting capacity. ML-T7 directly exerts antitumor efficacy in preclinical tumor models either alone or in combination with Nivolumab (HY-P9903A). ML-T7 can be used for tumor immunotherapy research[1].
• Target Antigen: Tim3
• Type: Reference compound
• Related Pathways: Immunology/Inflammation
• Applications: Cancer-programmed cell death
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/ml-t7.html
• Solubility: DMSO : 66.67 mg/mL (ultrasonic)
• Smiles: O=C1C2=C(C(C13OC(C4C(N(C5=CC=C(C=C5Cl)Cl)C(C43)=O)=O)C6=CC=C(C)C=C6)=O)C=CC=C2
• Molecular Weight: 506.33
• References & Citations: [1]Ma S, et al. Identification of a small-molecule Tim-3 inhibitor to potentiate T cell-mediated antitumor immunotherapy in preclinical mouse models. Sci Transl Med. 2023 Nov 15;15(722):eadg6752.
• Shipping Conditions: Room Temperature
• Clinical Information: No Development Reported